Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Cash & Equivalents: 2017-2018

Historic Cash & Equivalents for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to $15.3 million.

  • Astria Therapeutics' Cash & Equivalents fell 10.62% to $17.8 million in Q3 2019 from the same period last year, while for Sep 2019 it was $17.8 million, marking a year-over-year decrease of 10.62%. This contributed to the annual value of $15.3 million for FY2018, which is 6.57% down from last year.
  • Latest data reveals that Astria Therapeutics reported Cash & Equivalents of $15.3 million as of FY2018, which was down 6.57% from $16.4 million recorded in FY2017.
  • Astria Therapeutics' Cash & Equivalents' 5-year high stood at $16.4 million during FY2017, with a 5-year trough of $15.3 million in FY2018.
  • In the last 2 years, Astria Therapeutics' Cash & Equivalents had a median value of $15.8 million in 2017 and averaged $15.8 million.
  • Data for Astria Therapeutics' Cash & Equivalents shows a maximum YoY declined of 6.57% (in 2018) over the last 5 years.
  • Over the past 2 years, Astria Therapeutics' Cash & Equivalents (Yearly) stood at $16.4 million in 2017, then decreased by 6.57% to $15.3 million in 2018.